Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BMS-986166 in Healthy Japanese Participants
NCT04965402Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of udifitimod in atopic dermatitis (AD) and ulcerative colitis (UC) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed blood concentration of BMS-986166 at Day 28, Time of maximum observed blood concentration of BMS-986166 at Day 28 and 4 more. Started Jul 2021; status: completed.
02
Drugs
udifitimod
03
Conditions
atopic dermatitis (AD)ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04965402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04965402.